找回密码

Loging

Eisai expands its anti-obesity drug market

Published: Tuesday, November 12th, 2013

Global pharmaceutical firm, Eisai has expanded the marketing and supply agreement between its U.S. subsidiary Eisai Inc. and U.S-based Arena Pharmaceuticals's Swiss subsidiary, Arena Pharmaceuticals, for anti-obesity agent lorcaserin hydrochloride (lorcaserin) (U.S. brand name: BELVIQ).

Share This Article

Global pharmaceutical firm, Eisai has expanded the marketing and supply agreement between its U.S. subsidiary Eisai Inc. and U.S-based Arena Pharmaceuticals’s Swiss subsidiary, Arena Pharmaceuticals, for anti-obesity agent lorcaserin hydrochloride (lorcaserin) (U.S. brand name: BELVIQ).

Whilst the existing agreement granted Eisai exclusive rights to market and distribute lorcaserin in 21 countries throughout US, the expanded agreement now includes most countries and territories worldwide, most notably, the member states of the European Union, Japan and China (but excludes South Korea, Taiwan, Australia, New Zealand and Israel).

Under this agreement, Eisai will be working in collaboration with Arena to develop and seek marketing authorisation of lorcaserin as an anti-obesity treatment in its territories. In addition to pursuing regulatory approval for weight management in the expanded territories, Eisai and Arena plan to investigate the potential of lorcaserin in new areas, such as: smoking cessation, a once-daily formulation, a fixed-dose combination with phentermine, as well as explore lorcaserin’s impact on diabetes and cardiovascular outcomes.

Related Topics and Key Words:

,

V免费订阅电子通讯

* 为必填
多久你想收到电子报? *

公司信息

888 Publishing Ltd


6 Mitre Passage
Greenwich Peninsula
London
SE10 0ER
CO:08048039
t: +44 203 440 7113
f: +44 203 440 7115


loading...
Please Wait...